Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
24 janv. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Neurology®, an international peer-reviewed journal, on Wednesday published the results of the HOPE-Duchenne clinical trial that evaluated the safety...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
22 janv. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive...
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13 nov. 2018 16h01 HE
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
12 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
08 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action...
Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
06 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6
02 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Presentation to Focus on Company’s Therapeutic Pipeline for Duchenne Muscular Dystrophy and other Rare Diseases LOS ANGELES, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:...
Capricor Therapeutics to Participate in Upcoming Conferences
22 oct. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
03 oct. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy,...
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
21 août 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the...